HEADER IMMUNOGLOBULIN 23-DEC-98 1IGA TITLE MODEL OF HUMAN IGA1 DETERMINED BY SOLUTION SCATTERING CURVE-FITTING TITLE 2 AND HOMOLOGY MODELLING COMPND MOL_ID: 1; COMPND 2 MOLECULE: IGA1; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: CHAINS A AND B, HEAVY, CHAINS C AND D, LIGHT; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: IGA1; COMPND 7 CHAIN: C, D; COMPND 8 FRAGMENT: CHAINS A AND B, HEAVY, CHAINS C AND D, LIGHT SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 OTHER_DETAILS: SEE PRIMARY REFERENCE FOR MORE DETAILS; SOURCE 6 MOL_ID: 2; SOURCE 7 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 8 ORGANISM_COMMON: HUMAN; SOURCE 9 ORGANISM_TAXID: 9606; SOURCE 10 OTHER_DETAILS: SEE PRIMARY REFERENCE FOR MORE DETAILS KEYWDS IMMUNOGLOBULIN, IGA1 EXPDTA SOLUTION SCATTERING MDLTYP CA ATOMS ONLY, CHAIN A, B, C, D AUTHOR M.K.BOEHM,J.M.WOOF,M.A.KERR,S.J.PERKINS REVDAT 4 07-FEB-24 1IGA 1 SEQADV REVDAT 3 07-APR-10 1IGA 1 REMARK REVDAT 2 24-FEB-09 1IGA 1 VERSN REVDAT 1 15-JUN-99 1IGA 0 JRNL AUTH M.K.BOEHM,J.M.WOOF,M.A.KERR,S.J.PERKINS JRNL TITL THE FAB AND FC FRAGMENTS OF IGA1 EXHIBIT A DIFFERENT JRNL TITL 2 ARRANGEMENT FROM THAT IN IGG: A STUDY BY X-RAY AND NEUTRON JRNL TITL 3 SOLUTION SCATTERING AND HOMOLOGY MODELLING. JRNL REF J.MOL.BIOL. V. 286 1421 1999 JRNL REFN ISSN 0022-2836 JRNL PMID 10064707 JRNL DOI 10.1006/JMBI.1998.2556 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.J.PERKINS,A.W.ASHTON,M.K.BOEHM,D.CHAMBERLAIN REMARK 1 TITL MOLECULAR STRUCTURES FROM LOW ANGLE X-RAY AND NEUTRON REMARK 1 TITL 2 SCATTERING STUDIES REMARK 1 REF INT.J.BIOL.MACROMOL. V. 22 1 1998 REMARK 1 REFN ISSN 0141-8130 REMARK 1 REFERENCE 2 REMARK 1 AUTH S.J.PERKINS,C.G.ULLMAN,N.C.BRISSETT,D.CHAMBERLAIN,M.K.BOEHM REMARK 1 TITL ANALOGY AND SOLUTION SCATTERING MODELLING: NEW STRUCTURAL REMARK 1 TITL 2 STRATEGIES FOR THE MULTIDOMAIN PROTEINS OF COMPLEMENT, REMARK 1 TITL 3 CARTILAGE AND THE IMMUNOGLOBULIN SUPERFAMILY REMARK 1 REF IMMUNOL.REV. V. 163 237 1998 REMARK 1 REFN ISSN 0105-2896 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : DISCOVER 3.0 REMARK 3 AUTHORS : REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1378 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1IGA COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000174144. REMARK 265 REMARK 265 EXPERIMENTAL DETAILS REMARK 265 REMARK 265 EXPERIMENT TYPE : SMALL ANGLE X-RAY SCATTERING REMARK 265 DATA ACQUISITION REMARK 265 RADIATION/NEUTRON SOURCE : SRS DARESBURY REMARK 265 SYNCHROTRON (Y/N) : Y REMARK 265 BEAMLINE TYPE : 2.1 REMARK 265 BEAMLINE INSTRUMENT : NULL REMARK 265 DETECTOR TYPE : QUADRANT DETECTOR REMARK 265 DETECTOR MANUFACTURER DETAILS : NULL REMARK 265 TEMPERATURE (KELVIN) : NULL REMARK 265 PH : NULL REMARK 265 NUMBER OF TIME FRAMES USED : 1 REMARK 265 PROTEIN CONCENTRATION RANGE (MG/ML) : NULL REMARK 265 SAMPLE BUFFER : NULL REMARK 265 DATA REDUCTION SOFTWARE : OTOKO REMARK 265 GUINIER MEAN RADIUS OF GYRATION (NM) : NULL REMARK 265 SIGMA MEAN RADIUS OF GYRATION : NULL REMARK 265 R(XS-1) MEAN CROSS SECTIONAL RADII (NM) : NULL REMARK 265 R(XS-1) SIGMA MEAN CROSS SECTIONAL RADII : NULL REMARK 265 R(XS-2) MEAN CROSS SECTIONAL RADII (NM) : NULL REMARK 265 R(XS-2) SIGMA MEAN CROSS SECTIONAL RADII : NULL REMARK 265 P(R) PROTEIN LENGTH (NM) : NULL REMARK 265 REMARK 265 EXPERIMENT TYPE : SMALL ANGLE NEUTRON SCATTERING REMARK 265 DATA ACQUISITION REMARK 265 RADIATION/NEUTRON SOURCE : ISIS RUTHERFORD REMARK 265 SYNCHROTRON (Y/N) : Y REMARK 265 BEAMLINE TYPE : LOQ REMARK 265 BEAMLINE INSTRUMENT : NULL REMARK 265 DETECTOR TYPE : HE-3 ORDELA DETECTOR REMARK 265 DETECTOR MANUFACTURER DETAILS : NULL REMARK 265 TEMPERATURE (KELVIN) : NULL REMARK 265 PH : NULL REMARK 265 NUMBER OF TIME FRAMES USED : 1 REMARK 265 PROTEIN CONCENTRATION RANGE (MG/ML) : NULL REMARK 265 SAMPLE BUFFER : NULL REMARK 265 DATA REDUCTION SOFTWARE : COLETTE REMARK 265 GUINIER MEAN RADIUS OF GYRATION (NM) : NULL REMARK 265 SIGMA MEAN RADIUS OF GYRATION : NULL REMARK 265 R(XS-1) MEAN CROSS SECTIONAL RADII (NM) : NULL REMARK 265 R(XS-1) SIGMA MEAN CROSS SECTIONAL RADII : NULL REMARK 265 R(XS-2) MEAN CROSS SECTIONAL RADII (NM) : NULL REMARK 265 R(XS-2) SIGMA MEAN CROSS SECTIONAL RADII : NULL REMARK 265 P(R) PROTEIN LENGTH (NM) : NULL REMARK 265 REMARK 265 DATA ANALYSIS AND MODEL FITTING: REMARK 265 METHOD USED TO DETERMINE THE STRUCTURE: SCATTERING FITTING, REMARK 265 ENERGY MINIMIZATION REMARK 265 SOFTWARE USED : INSIGHT II, DISCOVERY 2.9.7, BIOSYM REMARK 265 SOFTWARE AUTHORS : NULL REMARK 265 STARTING MODEL : NULL REMARK 265 REMARK 265 CONFORMERS, NUMBER CALCULATED : NULL REMARK 265 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 265 CONFORMERS, SELECTION CRITERIA : NULL REMARK 265 REMARK 265 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 265 REMARK 265 OTHER DETAILS: THE MODEL OF HUMAN IGA1 WAS BASED ON SEVERAL REMARK 265 IMMUNOGLOBULIN CRYSTAL STRUCTURES FROM THE PDB. AN IGA1 MONOMER REMARK 265 CONTAINS TWELVE DOMAINS ON TWO FOUR-DOMAIN HEAVY CHAINS AND TWO REMARK 265 TWO-DOMAIN LIGHT CHAINS. THE CHAINS ASSOCIATE TO FORM TWO FOUR- REMARK 265 DOMAIN FAB FRAGMENTS AND ONE FOUR-DOMAIN FC FRAGMENT. EACH FAB REMARK 265 FRAGMENT IS JOINED TO THE FC FRAGMENT BY A 23-RESIDUE PEPTIDE REMARK 265 LINKER. THERE ARE SIX DOMAIN TYPES IN IGA1 (VH, CH1, CH2, CH3, REMARK 265 VL AND CL), AND A MONOMER CONTAINS TWO COPIES OF EACH DOMAIN- REMARK 265 TYPE. THE SEQUENCES OF THE CH1, CH2 AND CH3 DOMAINS ARE SPECIFIC REMARK 265 TO IGA1. REFINEMENT WAS CARRIED OUT USING DISCOVER 2.9.7, REMARK 265 BIOSYM. ALSO USED ENERGY MINIMISATION. THE IGA1 CH1 DOMAIN WAS REMARK 265 MODELLED USING THE CORRESPONDING DOMAIN FROM THE THE MOUSE IGA REMARK 265 J539 FAB STRUCTURE (CODE: 2FBJ) AND THE HUMAN IGG1 TR1.9 FAB REMARK 265 STRUCTURE (CODE: 1VGE) AS TEMPLATES. THE IGA1 CH2 AND CH3 REMARK 265 DOMAINS WERE MODELLED USING THE CORRESPONDING DOMAINS FROM THE REMARK 265 HUMAN IGG1 FC STRUCTURE (CODE: 1FC1) AS TEMPLATES. THE REMAINING REMARK 265 DOMAINS IN THE IGA1 MODEL (VL, CL AND VH) USED THE APPROPRIATE REMARK 265 DOMAINS FROM THE TR1.9 FAB STRUCTURE DIRECTLY. EACH FAB FRAGMENT REMARK 265 CONTAINS A SINGLE COPY OF THE VH, CH1, VL AND CL DOMAINS, AND REMARK 265 THEIR ARRANGEMENT WAS BASED DIRECTLY ON THE TR1.9 FAB STRUCTURE. REMARK 265 IN THE FC STRUCTURE, TWO COPIES OF THE CH2 AND CH3 DOMAINS WERE REMARK 265 USED. THEIR ARRANGEMENT WAS BASED ON THAT IN THE HUMAN IGG1 FC REMARK 265 STRUCTURE (CODE 1FC1) EXCEPT THAT THE TWO CH2 DOMAINS WERE REMARK 265 REORIENTATED AND REMODELLED SLIGHTLY TO ACCOMMODATE A PROPOSED REMARK 265 DISULPHIDE BRIDGING PATTERN. THE POSITIONS OF THE FAB FRAGMENTS REMARK 265 RELATIVE TO THE FC FRAGMENT WERE DETERMINED BY AN APPROACH THAT REMARK 265 COMBINED RANDOM HINGE PEPTIDE STRUCTURES PRODUCED BY MOLECULAR REMARK 265 DYNAMICS SIMULATIONS WITH CURVE-FITTING TO EXPERIMENTAL SOLUTION REMARK 265 SCATTERING DATA. A SINGLE ARRANGEMENT OF THE FAB FRAGMENTS IS REMARK 265 PRESENTED, WHICH IS REPRESENTATIVE OF A FAMILY OF STRUCTURES REMARK 265 THAT FIT THE SCATTERING DATA. IN ADDITION, IGA1 CONTAINS AN 18- REMARK 265 RESIDUE TAILPIECE PEPTIDE AT THE C-TERMINAL OF EACH CH3 DOMAIN. REMARK 265 THE TAILPIECE STRUCTURE PRODUCED BY MOLECULAR DYNAMICS REMARK 265 SIMULATIONS THAT BEST-FITTED THE EXPERIMENTAL DATA IS SHOWN ON REMARK 265 EACH MODEL. MORE DETAILS ON THE MODELLING STRATEGY ARE CONTAINED REMARK 265 IN THE PRIMARY REFERENCE. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 DBREF 1IGA A 123 475 UNP P01876 IGHA1_HUMAN 1 353 DBREF 1IGA B 123 475 UNP P01876 IGHA1_HUMAN 1 353 DBREF 1IGA C 1 214 EMBL X95747 CAA65058 23 234 DBREF 1IGA D 1 214 EMBL X95747 CAA65058 23 234 SEQADV 1IGA VAL C 3 EMBL X95747 INSERTION SEQADV 1IGA MET C 4 EMBL X95747 INSERTION SEQADV 1IGA LEU C 11 EMBL X95747 VAL 31 CONFLICT SEQADV 1IGA ASN C 20 EMBL X95747 THR 40 CONFLICT SEQADV 1IGA ALA C 22 EMBL X95747 THR 42 CONFLICT SEQADV 1IGA ALA C 32 EMBL X95747 TRP 52 CONFLICT SEQADV 1IGA ARG C 45 EMBL X95747 LYS 65 CONFLICT SEQADV 1IGA ASP C 50 EMBL X95747 SER 70 CONFLICT SEQADV 1IGA ASN C 53 EMBL X95747 SER 73 CONFLICT SEQADV 1IGA GLU C 55 EMBL X95747 GLN 75 CONFLICT SEQADV 1IGA THR C 72 EMBL X95747 SER 92 CONFLICT SEQADV 1IGA PHE C 83 EMBL X95747 SER 103 CONFLICT SEQADV 1IGA ILE C 85 EMBL X95747 THR 105 CONFLICT SEQADV 1IGA PHE C 91 EMBL X95747 ALA 111 CONFLICT SEQADV 1IGA TYR C 94 EMBL X95747 PHE 114 CONFLICT SEQADV 1IGA LEU C 96 EMBL X95747 TYR 116 CONFLICT SEQADV 1IGA GLY C 100 EMBL X95747 GLN 120 CONFLICT SEQADV 1IGA VAL C 191 EMBL X95747 LEU 211 CONFLICT SEQADV 1IGA VAL D 3 EMBL X95747 INSERTION SEQADV 1IGA MET D 4 EMBL X95747 INSERTION SEQADV 1IGA LEU D 11 EMBL X95747 VAL 31 CONFLICT SEQADV 1IGA ASN D 20 EMBL X95747 THR 40 CONFLICT SEQADV 1IGA ALA D 22 EMBL X95747 THR 42 CONFLICT SEQADV 1IGA ALA D 32 EMBL X95747 TRP 52 CONFLICT SEQADV 1IGA ARG D 45 EMBL X95747 LYS 65 CONFLICT SEQADV 1IGA ASP D 50 EMBL X95747 SER 70 CONFLICT SEQADV 1IGA ASN D 53 EMBL X95747 SER 73 CONFLICT SEQADV 1IGA GLU D 55 EMBL X95747 GLN 75 CONFLICT SEQADV 1IGA THR D 72 EMBL X95747 SER 92 CONFLICT SEQADV 1IGA PHE D 83 EMBL X95747 SER 103 CONFLICT SEQADV 1IGA ILE D 85 EMBL X95747 THR 105 CONFLICT SEQADV 1IGA PHE D 91 EMBL X95747 ALA 111 CONFLICT SEQADV 1IGA TYR D 94 EMBL X95747 PHE 114 CONFLICT SEQADV 1IGA LEU D 96 EMBL X95747 TYR 116 CONFLICT SEQADV 1IGA GLY D 100 EMBL X95747 GLN 120 CONFLICT SEQADV 1IGA VAL D 191 EMBL X95747 LEU 211 CONFLICT SEQRES 1 A 475 GLN VAL LYS LEU LEU GLU GLN SER GLY ALA GLU VAL LYS SEQRES 2 A 475 LYS PRO GLY ALA SER VAL LYS VAL SER CYS LYS ALA SER SEQRES 3 A 475 GLY TYR SER PHE THR SER TYR GLY LEU HIS TRP VAL ARG SEQRES 4 A 475 GLN ALA PRO GLY GLN ARG LEU GLU TRP MET GLY TRP ILE SEQRES 5 A 475 SER ALA GLY THR GLY ASN THR LYS TYR SER GLN LYS PHE SEQRES 6 A 475 ARG GLY ARG VAL THR PHE THR ARG ASP THR SER ALA THR SEQRES 7 A 475 THR ALA TYR MET GLY LEU SER SER LEU ARG PRO GLU ASP SEQRES 8 A 475 THR ALA VAL TYR TYR CYS ALA ARG ASP PRO TYR GLY GLY SEQRES 9 A 475 GLY LYS SER GLU PHE ASP TYR TRP GLY GLN GLY THR LEU SEQRES 10 A 475 VAL THR VAL SER SER ALA SER PRO THR SER PRO LYS VAL SEQRES 11 A 475 PHE PRO LEU SER LEU CYS SER THR GLN PRO ASP GLY ASN SEQRES 12 A 475 VAL VAL ILE ALA CYS LEU VAL GLN GLY PHE PHE PRO GLN SEQRES 13 A 475 GLU PRO LEU SER VAL THR TRP SER GLU SER GLY GLN GLY SEQRES 14 A 475 VAL THR ALA ARG ASN PHE PRO PRO SER GLN ASP ALA SER SEQRES 15 A 475 GLY ASP LEU TYR THR THR SER SER GLN LEU THR LEU PRO SEQRES 16 A 475 ALA THR GLN CYS LEU ALA GLY LYS SER VAL THR CYS HIS SEQRES 17 A 475 VAL LYS HIS TYR THR ASN PRO SER GLN ASP VAL THR VAL SEQRES 18 A 475 PRO CYS PRO VAL PRO SER THR PRO PRO THR PRO SER PRO SEQRES 19 A 475 SER THR PRO PRO THR PRO SER PRO SER CYS CYS HIS PRO SEQRES 20 A 475 ARG LEU SER LEU HIS ARG PRO ALA LEU GLU ASP LEU LEU SEQRES 21 A 475 LEU GLY SER GLU ALA ASN LEU THR CYS THR LEU THR GLY SEQRES 22 A 475 LEU ARG ASP ALA SER GLY VAL THR PHE THR TRP THR PRO SEQRES 23 A 475 SER SER GLY LYS SER ALA VAL GLN GLY PRO PRO GLU ARG SEQRES 24 A 475 ASP LEU CYS GLY CYS TYR SER VAL SER SER VAL LEU PRO SEQRES 25 A 475 GLY CYS ALA GLU PRO TRP ASN HIS GLY LYS THR PHE THR SEQRES 26 A 475 CYS THR ALA ALA TYR PRO GLU SER LYS THR PRO LEU THR SEQRES 27 A 475 ALA THR LEU SER LYS SER GLY ASN THR PHE ARG PRO GLU SEQRES 28 A 475 VAL HIS LEU LEU PRO PRO PRO SER GLU GLU LEU ALA LEU SEQRES 29 A 475 ASN GLU LEU VAL THR LEU THR CYS LEU ALA ARG GLY PHE SEQRES 30 A 475 SER PRO LYS ASP VAL LEU VAL ARG TRP LEU GLN GLY SER SEQRES 31 A 475 GLN GLU LEU PRO ARG GLU LYS TYR LEU THR TRP ALA SER SEQRES 32 A 475 ARG GLN GLU PRO SER GLN GLY THR THR THR PHE ALA VAL SEQRES 33 A 475 THR SER ILE LEU ARG VAL ALA ALA GLU ASP TRP LYS LYS SEQRES 34 A 475 GLY ASP THR PHE SER CYS MET VAL GLY HIS GLU ALA LEU SEQRES 35 A 475 PRO LEU ALA PHE THR GLN LYS THR ILE ASP ARG LEU ALA SEQRES 36 A 475 GLY LYS PRO THR HIS VAL ASN VAL SER VAL VAL MET ALA SEQRES 37 A 475 GLU VAL ASP GLY THR CYS TYR SEQRES 1 B 475 GLN VAL LYS LEU LEU GLU GLN SER GLY ALA GLU VAL LYS SEQRES 2 B 475 LYS PRO GLY ALA SER VAL LYS VAL SER CYS LYS ALA SER SEQRES 3 B 475 GLY TYR SER PHE THR SER TYR GLY LEU HIS TRP VAL ARG SEQRES 4 B 475 GLN ALA PRO GLY GLN ARG LEU GLU TRP MET GLY TRP ILE SEQRES 5 B 475 SER ALA GLY THR GLY ASN THR LYS TYR SER GLN LYS PHE SEQRES 6 B 475 ARG GLY ARG VAL THR PHE THR ARG ASP THR SER ALA THR SEQRES 7 B 475 THR ALA TYR MET GLY LEU SER SER LEU ARG PRO GLU ASP SEQRES 8 B 475 THR ALA VAL TYR TYR CYS ALA ARG ASP PRO TYR GLY GLY SEQRES 9 B 475 GLY LYS SER GLU PHE ASP TYR TRP GLY GLN GLY THR LEU SEQRES 10 B 475 VAL THR VAL SER SER ALA SER PRO THR SER PRO LYS VAL SEQRES 11 B 475 PHE PRO LEU SER LEU CYS SER THR GLN PRO ASP GLY ASN SEQRES 12 B 475 VAL VAL ILE ALA CYS LEU VAL GLN GLY PHE PHE PRO GLN SEQRES 13 B 475 GLU PRO LEU SER VAL THR TRP SER GLU SER GLY GLN GLY SEQRES 14 B 475 VAL THR ALA ARG ASN PHE PRO PRO SER GLN ASP ALA SER SEQRES 15 B 475 GLY ASP LEU TYR THR THR SER SER GLN LEU THR LEU PRO SEQRES 16 B 475 ALA THR GLN CYS LEU ALA GLY LYS SER VAL THR CYS HIS SEQRES 17 B 475 VAL LYS HIS TYR THR ASN PRO SER GLN ASP VAL THR VAL SEQRES 18 B 475 PRO CYS PRO VAL PRO SER THR PRO PRO THR PRO SER PRO SEQRES 19 B 475 SER THR PRO PRO THR PRO SER PRO SER CYS CYS HIS PRO SEQRES 20 B 475 ARG LEU SER LEU HIS ARG PRO ALA LEU GLU ASP LEU LEU SEQRES 21 B 475 LEU GLY SER GLU ALA ASN LEU THR CYS THR LEU THR GLY SEQRES 22 B 475 LEU ARG ASP ALA SER GLY VAL THR PHE THR TRP THR PRO SEQRES 23 B 475 SER SER GLY LYS SER ALA VAL GLN GLY PRO PRO GLU ARG SEQRES 24 B 475 ASP LEU CYS GLY CYS TYR SER VAL SER SER VAL LEU PRO SEQRES 25 B 475 GLY CYS ALA GLU PRO TRP ASN HIS GLY LYS THR PHE THR SEQRES 26 B 475 CYS THR ALA ALA TYR PRO GLU SER LYS THR PRO LEU THR SEQRES 27 B 475 ALA THR LEU SER LYS SER GLY ASN THR PHE ARG PRO GLU SEQRES 28 B 475 VAL HIS LEU LEU PRO PRO PRO SER GLU GLU LEU ALA LEU SEQRES 29 B 475 ASN GLU LEU VAL THR LEU THR CYS LEU ALA ARG GLY PHE SEQRES 30 B 475 SER PRO LYS ASP VAL LEU VAL ARG TRP LEU GLN GLY SER SEQRES 31 B 475 GLN GLU LEU PRO ARG GLU LYS TYR LEU THR TRP ALA SER SEQRES 32 B 475 ARG GLN GLU PRO SER GLN GLY THR THR THR PHE ALA VAL SEQRES 33 B 475 THR SER ILE LEU ARG VAL ALA ALA GLU ASP TRP LYS LYS SEQRES 34 B 475 GLY ASP THR PHE SER CYS MET VAL GLY HIS GLU ALA LEU SEQRES 35 B 475 PRO LEU ALA PHE THR GLN LYS THR ILE ASP ARG LEU ALA SEQRES 36 B 475 GLY LYS PRO THR HIS VAL ASN VAL SER VAL VAL MET ALA SEQRES 37 B 475 GLU VAL ASP GLY THR CYS TYR SEQRES 1 C 214 GLU LEU VAL MET THR GLN SER PRO SER SER LEU SER ALA SEQRES 2 C 214 SER VAL GLY ASP ARG VAL ASN ILE ALA CYS ARG ALA SER SEQRES 3 C 214 GLN GLY ILE SER SER ALA LEU ALA TRP TYR GLN GLN LYS SEQRES 4 C 214 PRO GLY LYS ALA PRO ARG LEU LEU ILE TYR ASP ALA SER SEQRES 5 C 214 ASN LEU GLU SER GLY VAL PRO SER ARG PHE SER GLY SER SEQRES 6 C 214 GLY SER GLY THR ASP PHE THR LEU THR ILE SER SER LEU SEQRES 7 C 214 GLN PRO GLU ASP PHE ALA ILE TYR TYR CYS GLN GLN PHE SEQRES 8 C 214 ASN SER TYR PRO LEU THR PHE GLY GLY GLY THR LYS VAL SEQRES 9 C 214 GLU ILE LYS ARG THR VAL ALA ALA PRO SER VAL PHE ILE SEQRES 10 C 214 PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY THR ALA SEQRES 11 C 214 SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO ARG GLU SEQRES 12 C 214 ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU GLN SER SEQRES 13 C 214 GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SER LYS SEQRES 14 C 214 ASP SER THR TYR SER LEU SER SER THR LEU THR LEU SER SEQRES 15 C 214 LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA CYS GLU SEQRES 16 C 214 VAL THR HIS GLN GLY LEU SER SER PRO VAL THR LYS SER SEQRES 17 C 214 PHE ASN ARG GLY GLU CYS SEQRES 1 D 214 GLU LEU VAL MET THR GLN SER PRO SER SER LEU SER ALA SEQRES 2 D 214 SER VAL GLY ASP ARG VAL ASN ILE ALA CYS ARG ALA SER SEQRES 3 D 214 GLN GLY ILE SER SER ALA LEU ALA TRP TYR GLN GLN LYS SEQRES 4 D 214 PRO GLY LYS ALA PRO ARG LEU LEU ILE TYR ASP ALA SER SEQRES 5 D 214 ASN LEU GLU SER GLY VAL PRO SER ARG PHE SER GLY SER SEQRES 6 D 214 GLY SER GLY THR ASP PHE THR LEU THR ILE SER SER LEU SEQRES 7 D 214 GLN PRO GLU ASP PHE ALA ILE TYR TYR CYS GLN GLN PHE SEQRES 8 D 214 ASN SER TYR PRO LEU THR PHE GLY GLY GLY THR LYS VAL SEQRES 9 D 214 GLU ILE LYS ARG THR VAL ALA ALA PRO SER VAL PHE ILE SEQRES 10 D 214 PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY THR ALA SEQRES 11 D 214 SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO ARG GLU SEQRES 12 D 214 ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU GLN SER SEQRES 13 D 214 GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SER LYS SEQRES 14 D 214 ASP SER THR TYR SER LEU SER SER THR LEU THR LEU SER SEQRES 15 D 214 LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA CYS GLU SEQRES 16 D 214 VAL THR HIS GLN GLY LEU SER SER PRO VAL THR LYS SER SEQRES 17 D 214 PHE ASN ARG GLY GLU CYS CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000